We have previously shown that recombinant interleukin 1 (IL-1) and recombinant tumour necrosis factor (TNF) synergistically stimulate phospholipase A2 release from mesangial cells. We now report that treatment of mesangial cells with the fl-agonist salbutamol, prostaglandin E2 (PGE2), cholera toxin or forskolin, which all activate adenylate cyclase, increased release of phospholipase A2 activity. Likewise, addition of a membrane-permeant cyclic AMP (cAMP) analogue or the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine enhanced release of phospholipase A2 activity from mesangial cells. There was a lag period of about 8 h before a significantly enhanced secretion could be detected. Angiotensin II, the phorbol ester phorbol 12-myristate 13-acetate, the Ca2+ ionophore A23187 and a membrane-permeant cGMP analogue did not stimulate phospholipase A2 release from the cells. Treatment with indomethacin completely inhibited IL-Ifl-and TNF-stimulated PGE2 synthesis, without having any effect on phospholipase A2 secretion, thus excluding cytokine-induced PGE2 synthesis as the mediator of phospholipase A2 release. Neither IL-If nor TNF induced any increase in intracellular cAMP in mesangial cells. Furthermore, incubation of the cells with 2',5'-dideoxyadenosine, an inhibitor of adenylate cyclase, did not block cytokine-stimulated phospholipase 42 secretion. In addition, IL-if1 and TNF synergistically interacted with forskolin to stimulate-phospholipase A2 release from the cells..The protein kinase inhibitors H-8, staurosporine, K252a and amiloride inhibited IL-If1-and TNF-stimulated phospholipase A2 secretion. However, high concentrations that inhibit other protein kinases were needed. These observations suggest that IL-lf, and TNF cause secretion of phospholipase A2 by a mechanism independent of cAMP. The signalling pathways used by
INTRODUCTION
IL-l and TNF are polypeptide mediators produced by a variety of cell types, and are a central factor in the development of immune and inflammatory processes (see [1] [2] [3] [4] 
for reviews).
Other reports have demonstrated that mesangial cells also express and secrete IL-1 [5, 6] and TNF [7] . The IL-I secreted by the cells was shown to stimulate proliferation in an autocrine manner [8, 9] . Thus the local release of growth factors such as IL-I may contribute to the development of glomerular hypercellularity, a characteristic feature of many forms of immune-mediated glomerulonephritis [10] . Werber et al. [6] reported augmented IL-1 gene expression in glomerular mesangial cells in immune-complex glomerulonephritis. Furthermore, IL-I stimulates the release of a specific type IV collagenase [11] , and both cytokines, IL-I and TNF, enhance the synthesis of prostaglandins by mesangial cells [12] [13] [14] . The interaction of monocytes, which represent the dominant cell type infiltrating the glomerulus in immune-mediated glomerulonephritis, and intrinsic mesangial cells plays a central role in the pathogenesis of these diseases. Recently, we have shown that a soluble phospholipase A2 is secreted from mesangial cells in response to IL-la, IL-i,8 and TNF [13] . Extracellular phospholipase A2 is proinflammatory and vasoactive, and mediates hyperaemia and a marked inflammatory reaction when injected intracutaneously into rabbits [15] or intra-articularly into rats [16] . In the present work we tried to gain further insight into the signalling mechanism involved in IL-1,i-and TNF-stimulated phospholipase A2 release from mesangial cells.
MATERIALS AND METHODS Cell culture
Rat mesangial cells were cultivated as described previously [17, 18] . The cells were grown in RPMI 1640 supplemented with 20% (v/v) fetal-calf serum, penicillin (100 units/ml), streptomycin (100 ,g/ml) and bovine insulin at 0.66 unit/ml (Sigma).
Mesangial cells were characterized morphologically by phasecontrast microscopy, positive staining for the intermediate filaments desmin and vimentin, which is considered to be specific for myogenic cells [19] , and negative staining for Factor VIII-related antigen and cytokeratin, excluding endothelial and epithelial contamination respectively. For the experiments passages of mesangial cells were used.
Incubation of cells and prostaglandin analysis
Confluent mesangial cells cultured in 16 mm-diameter wells were washed twice with phosphate-buffered saline (137 mMNaCl/2.7 mM-KCI/8 mM-Na2HPO4/1.5 mM-KH2PO4) and incubated with 1 Phospholipase A2 assay Phospholipase A2 activity was determined with [1-'4C]oleatelabelled Escherichia coli as substrate as described previously [21] . The substrate was prepared by growing E. coli in the presence of [1-14C] oleate, followed by autoclaving to inactivate endogenous phospholipases. Over 95 % of the label incorporated by E. coli was in phospholipid and, as demonstrated by hydrolysis with snake venom (Crotalus adamanteus), more than 95 % of the [1-14C] oleate was in the sn-2 position of the phospholipids [21] . Assay mixtures (1.0 ml) contained 100 mM-Tris/HCl buffer (pH 7.0), 1.0 mM-CaCl2, 2.5 x 108 [1-_4C]oleate-labelled E. coli (5 nmol of phospholipid, 5000-8000 c.p.m.) and the enzyme to be tested at a dilution producing 10-15% substrate hydrolysis. Reaction mixtures were incubated for 1 h at 37°C in a shaking water bath. The reaction was stopped by the addition of 5 ml of propan-2-ol/n-heptane/1 M-H2SO4 (40: 10: 1, by vol.) followed by 2 ml of heptane and 3 ml of water. After vigorous shaking and phase separation, a portion (2.5 ml) of the upper phase was passed over a column of silicic acid (3.5 cm x 0.5 cm). Free [1-14C] anism involved in this cell response.. As shown in Fig. 1 and Table 1 mesangial cells spontaneously released phospholipase A2 activity at a low rate. Addition of forskolin (10 M), a potent activator of adenylate cyclase, resulted in a significant increase in the rate of phospholipase A2 secretion after a lag time of 8 h. A similar lag period of 8 h has been observed for IL-Ilfl-stimulated phospholipase A2 release [13] . The response to forskolin was dose-dependent, with a threshold at 0.1 aM-forskolin, and maximal effect at 100 1sM-forskolin. Like the IL-1,/-induced phospholipase A2 [13] , the forskolin-induced enzyme had a neutral pH optimum and the activity was critically dependent on free (n = 4). Ca2+ concentration, with significant activity in the low-micromolar range (results not shown). The 1,9-dideoxy derivative of forskolin, which is unable to activate adenylate cyclase [22] , had no effect on phospholipase A2 release from mesangial cells (Table  1) , thus indicating that it was not a non-specific effect of forskolin that caused the enhanced secretion of phospholipase A2 from mesangial cells. The diterpene forskolin is known to activate adenylate cyclase by direct stimulation of the catalytic subunit of the enzyme [22] . In a further approach we used salbutamol and cholera toxin, two compounds that activate the adenylate cyclase system by different mechanisms. Salbutamol binds to ,/-adrenergic receptors on the cell surface of mesangial cells and activates adenylate cyclase via the stimulatory G-protein, GS [22] .
Cholera toxin causes ADP-ribosylation of G., thus altering this G-protein to a state of permanent activation, leading to the subsequent stimulation of the catalytic moiety of adenylate cyclase. As shown in Table 1 , both agents enhanced phospholipase A2 release from mesangial cells. In a next step we used the membrane-permeant analogue of cAMP, Bt2cAMP, to elevate the intracellular concentration ofcAMP directly. The data in Table 1 clearly show that Bt2cAMP increased the release of phospholipase A2 activity. In addition, the phosphodiesterase inhibitor 3-isobutyl-I -methylxanthine, which increases cAMP by inhibiting the enzyme that degrades it, also enhanced phospholipase A2 release ( Table 1) . As reported for the IL-1-and TNF-stimulated phospholipase A2 release [13] , addition of actinomycin D (10 gM) or cycloheximide (10 #M) at the time of stimulation completely suppressed the forskolin-induced enzyme release from mesangial cells (Table 1) . Actinomycin D and cycloheximide also suppressed the basal rate of secretion of phospholipase A2 (Table 1) .
Stimulation of phosphoinositide hydrolysis, protein kinase C, Ca2+ mobilization and cGMP generation has no effect on phospholipase A2 release It has been reported that the chemotactic peptide fMet-LeuPhe stimulates phospholipase A2 secretion from rabbit peritoneal neutrophils [23] . fMet-Leu-Phe is a potent activator of phospholipase C-mediated phosphoinositide hydrolysis in neutrophils [24, 25] . In order to elucidate a possible involvement of phosphoinositide turnover in phospholipase A2 secretion from mesangial cells, we tested the effect of angiotensin II, which is known to activate phospholipase C in these cells (see [26] for review). Furthermore, we checked the effects of PMA, a potent activator of protein kinase C, and the Ca2+ ionophore A23187 on enzyme secretion. As shown in Table 1 , neither angiotensin II (100 nM) or PMA (100 nM) or A23187 (10 /SM), nor a combination of PMA and A23187, had any effect on phospholipase A2 release from mesangial cells, thus excluding a possible contribution ofphospholipase C-triggered signalling pathways. In addition, the membrane-permeant analogue of cGMP, Bt2cGMP, was equally ineffective in stimulating phospholipase A2 release (Table 1) . From all these results it is tempting to speculate that cAMP may be the messenger of IL-l-and TNF-stimulated phospholipase A2 secretion from mesangial cells.
Inhibition of prostaglandin synthesis does not inhibit phospholipase A2 release Previously we have shown that IL-l and TNF synergistically stimulate release of phospholipase A2 as well as PGE2 from the mesangial cells [13] . As PGE2 and PGI2 have been shown to stimulate cAMP generation in mesangial cells [27] , one might assume that cytokine-stimulated PG formation and subsequent cAMP generation is responsible for the observed phospholipase A2 secretion. However, PG concentrations as high as 1 ,UM, two to three orders of magnitude higher than the values found after cytokine stimulation, were needed in order to see significant increases in intracellular cAMP levels [27] . Table 2 . In contrast, 2',5'-dideoxyadenosine not only blocked PGE2-stimulated cAMP formation (results not shown), but also inhibited PGE2-induced phospholipase A2 secretion (Table 2 ).
Forskolin and IL-1lp or TNF synergistically interact to stimulate phospholipase A2 secretion Agonists that share identical signalling mechanisms should display additive effects when combined at sub-optimal con- centrations, but not at optimal doses. Fig. 3 shows that forskolin dose-dependently stimulated phospholipase A2 secretion, reaching a plateau between 10 and 100 uM. IL-I, also stimulates phospholipase A2 release in a dose-dependent manner. When IL-1,i and forskolin were added simultaneously, there was a synergistic interaction over the whole dose-response range, as shown in Fig. 3 . Similarly, TNF and forskolin interact in a synergistic fashion to stimulate phospholipase A2 release from mesangial cells (Table 3 ). These data provide further evidence that IL-1 and TNF use signalling pathways different from the adenylate cyclase system in order to stimulate phospholipase A2 secretion from mesangial cells.
Protein kinase inhibitors attenuate phospholipase A2 release
In a further approach we used different protein kinase inhibitors in an attempt to determine the signalling cascades in cytokine-stimulated phospholipase A2 release. The isoquinoline H-8 has been reported to selectively inhibit cAMP-dependent and cGMP-dependent protein kinases, with K, values of 1.2 zm and 0.48 uM respectively [35] . Fig. 4 shows that H-8 dosedependently inhibited IL-I1b1-and TNF-stimulated phospholipase A2 release. However, concentrations as high as 50,UM were needed to obtain a significant inhibition of phospholipase A2 release. In addition, H-8 also blocked forskolin-stimulated phospholipase A2 secretion, but again 50,M-H-8 was needed to A, 100 pM; A, 500 pm; El, 2 nM; E, 10 nM. After the incubation period, the medium was withdrawn and phospholipase A2 activity was determined as outlined in the Materials and methods section.
Results are means+ S.E.M. (n = 4). Table 4 . Effects of protein kinase inhibitors on IL-ill-stimulated phospholipase A2 release from mesangial cells Confluent mesangial cells were incubated with the indicated compounds for 24 h. After the incubation period, the medium was removed and phospholipase A2 activity was determined as outlined in the Materials and methods section. Results are means+S.E.M.
(n = 4).
[ block the response (results not shown). Therefore, these data do not necessarily argue against cAMP-dependent protein kinase mediating cytokine-induced enzyme release. Staurosporine and its derivative K-252a were reported as potent inhibitors of protein kinase C, with 50 % inhibition at 2.7 nm and 25 nM respectively [36, 37] . Both compounds also inhibited IL-1l,-and TNF-stimulated phospholipase A2 release, as shown in Table 4 . However, concentrations far beyond those needed to inhibit protein kinase C were necessary to inhibit cytokine-induced enzyme release. These results agree well with the lack of activity of PMA in inducing phospholipase A2 secretion (Table 1) . Together, these data suggest that protein kinase C is not involved in IL-,l8-and TNF-induced enzyme release. We next used the diuretic agent amiloride, a non-specific inhibitor of protein kinases, previously shown to block epidermal-growth-factor receptor autophosphorylation and serine/threonine phosphorylation in intact cells [38, 39] . As shown in Table 4 , amiloride attenuates IL-l,8-and TNF-induced phospholipase A2 release.
DISCUSSION
Phospholipase A2 is a lipolytic enzyme that cleaves the 2-acyl fatty acid ester of glycerophospholipids with subsequent liberation of free fatty acids, especially arachidonic acid for further metabolism to prostaglandins and other eicosanoids. Eicosanoids, as well as phospholipase A2 itself, play an important role in inflammatory processes (see [40] for review). The extracellular secretion of a soluble phospholipase A2 was first reported from stimulated macrophages [41] and neutrophils [23] , and from aggregated platelets [42] . Stimulation and release of phospholipase A2 by IL-I and TNF was observed in rat and rabbit chondrocytes [43, 44] , as well as in human synovial cells [45, 46] .
Recently, we have reported that IL-1 and TNF interact synergistically to stimulate phospholipase A2 secretion from rat glomerular mesangial cells [13] . This enzyme secretion may play a role in the propagation of inflammatory reactions within the glomerulus. The signal transduction mechanism by which IL-I and TNF exert their effect on target cells is still largely unknown. In order to unveil the biochemical mechanisms whereby IL-I and TNF cause phospholipase A2 release from mesangial cells, we tested several compounds known to activate different signalling pathways on their ability to mimic cytokine-stimulated effects. As fMet-Leu-Phe and thrombi-n have been reported to stimulate. phospholipase A2 secretion from neutrophils [23] and platelets [42] , respectively, and both agonists activate phosphoinositide hydrolysis in these cells [24, 25, 47, 48] , we investigated the possible role of this important signalling cascade in phospholipase A2 release from mesangial cells. Addition of angiotensin II, a potent activator of phosphoinositide turnover in mesangial cells [26] , had no effect on phospholipase A2 release from the cells. Likewise, addition of PMA, an activator of protein kinase C, or addition of the Ca2+ ionophore A23187 had no effect on phospholipase secretion. Furthermore, neither IL-I nor TNF stimulated inositol polyphosphate generation and Ca2+ mobilization in mesangial cells (J. Pfeilschifter, unpublished work). This clearly shows that the bifurcating inositol lipid pathway does not contribute to the cytokine-stimulated phospholipase A2 secretion from mesangial cells. Likewise, the addition ofthe cell-permeant cGMP analogue, Bt2cGMP, did not stimulate phospholipase A2 secretion, thus excluding cGMP as a possible messenger. In contrast, activation of the adenylate cyclase system consistently enhanced phospholipase A2 release from mesangial cells. The time course of forskolin-stimulated phospholipase A2 secretion as well as the pH-and Ca2+ + dependence of the released enzyme were similar to those ofthe IL-I-and TNF-induced enzyme [13] . Furthermore, it has recently been demonstrated that cAMP mediates phospholipase A2 secretion from vascular smooth-muscle cells [49] . From [50] showed that cAMP analogues and cAMPinducing agents can replace IL-1 in the induction of interleukin 2 receptors on lymphocytes as well as in phytohaemagglutinininduced murine thymocyte proliferation. Those authors also demonstrated that IL-1 stimulates a rapid and marked synthesis of cAMP in the IL-I target cells. Activation of adenylate cyclase and cAMP-dependent protein kinase has also been suggested to play a role in IL-6-gene activation by TNF and IL-I in fibroblasts [51, 52] . In the mouse pituitary cell line AtT-20, IL-I itself has no effect on cAMP, but IL-1 potentiates the forskolin-stimulated secretion of /3-endorphin in a way similar to the synergistic interaction of IL-1 and forskolin in phospholipase secretion reported in the present paper [53] . In Jurkat T cells IL-I does not modify the intracellular levels of cAMP and cGMP [54] . Ob [12] [13] [14] , and PGE2 in turn is known to stimulate adenylate cyclase in the cells [27] . However, the potent cyclo-oxygenase inhibitors indomethacin (Fig. 2) and dciclofenac [28] completely abolished IL-I-and TNFstimulated prostaglandin synthesis without affecting phosphoVol. 273 lipase A2 release, thus excluding prostaglandins as the mediators of cytokine-induced enzyme secretion from mesangial cells. Obviously, the amounts of prostaglandins formed in response to IL-I or TNF are far below the concentrations needed to stimulate cAMP formation in mesangial cells. Furthermore, angiotensin II, which is a potent stimulator of prostaglandin synthesis in mesangial cells [56] , has no effect on phospholipase A2 release (Table 1 ). Lovett and colleagues [57] reported that IL-1 activates protein kinases in cultured glomerular mesangial cells. The kinase activation resulted in the phosphorylation of three predominant proteins. Specific tyrosine phosphorylation occurred at a 46 kDa protein, whereas a 55 kDa protein and a 20 kDa protein were phosphorylated on serine residues. In this connection it is noteworthy that different protein kinase inhibitors such as H-8, staurosporine, K-252a and amiloride were able to block IL-1-and TNF-induced phospholipase A2 secretion from mesangial cells (Fig. 4, Table 4 ). With regard to the paper by Lovett et al. [57] , a protein tyrosine kinase would be an attractive candidate for mediating phospholipase A2 release from mesangial cells. Work is needed to test this hypothesis and may help to design effective therapeutic compounds to counteract the inflammatory effects of extracellular phospholipase A2. The pathophysiological significance of cAMP-mediated phospholipase A2 release from glomerular mesangial cells and its possible role in the pathogenesis of glomerulonephritis remain to be elucidated.
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